体外研究
Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to N-desmethylclobazam (NCLB) mediated by CYP3A4 (noncompetitively) and CYP2C19 (competitively). The inhibition of CLB demethylation by Stiripentol (STP) is best described by a noncompetitive inhibition model with apparent K
i
=1.6 μM for the cDNA-expressing CYP3A4 and by a competitive inhibition model with K
i
=0.52 μM for the cDNA-expressing CYP2C19. Formation of OH-NCLB from NCLB by cDNA-expressing CYP2C19 is competitively inhibited by Stiripentol (STP) with a K
i
=0.14 μM.
LogP
3.39
MLOGP
2.25
WLOGP
2.73
XLogP3
4.16
iLOGP
3.13
储存条件
<0°C;避免加热
外观
白色至米色粉末
密度
1.1±0.1 g/cm³
折射率
1.579
拓扑极性表面积
38.69 Ų
水溶解性
0.0247 mg/ml
沸点
365.4±11.0 °C (760 mmHg)
溶解度
二甲基亚砜:≥20mg/mL
熔点
73-74 °C
精确质量
234.125595
蒸气压
0.0±0.9 mmHg (25 °C)
酸度系数(pKa)
14.45±0.20 (Predicted)
闪点
174.8±19.3 °C
体内研究
In mice treating with Stiripentol (STP) monotherapy, the difference between BT
1
(39.67±1.09°C) and BT
2
(41.32±1.05°C) reaches statistical significance (t=3.097, p<0.05). The difference in BT
2
between Stiripentol (STP) monotherapy and CLB monotherapy is statistically significant (t=2.615, p<0.05). In mice treating with Stiripentol (STP)+CLB combination therapy, the difference between BT
1
(40.18±0.58°C) and BT
2
(43.03±0.49°C) reaches statistical significance (t=10.44, p<0.01).